It's Monday madness.
Or maybe, final-week-of-July-madness is more acceptable.
Jim Cramer's got some thoughts on Starbucks (SBUX) - Get Starbucks Corporation Report and how CEO Kevin Johnson's doing at the helm, what he's expecting from a week that's poised to be news-heavy and what he's thinking about Pfizer's (PFE) - Get Pfizer Inc. Report plan to spin off its off-patent drug business with Mylan MYL.
A few notable market events: We're hearing from over 1,400 companies--including Apple (AAPL) - Get Apple Inc. (AAPL) Report , Beyond Meat (BYND) - Get Beyond Meat, Inc. Report and General Electric (GE) - Get General Electric Company (GE) Report --and then we have the Federal Reserve's decision, news from the trade talks and, finally, the jobs report number on Friday.
You know, in case you didn't have enough on your plates already.
But it's okay, Cramer's got some thoughts on how investors can take a breath and regroup before deep-diving into the earnings calls.
Jim Cramer had some positive things to say about the popular coffee chain.
Well, I guess it's more accurate to say coffee-and-food chain, according to Cramer's Real Money column Monday morning.
Cramer noted how successful Starbucks has been under the leadership of CEO Kevin Johnson--the stock is up around 90% in the past year, and Cramer likes how Johnson is getting customers in the door for more than just coffee.
Here's a sneak peek of Cramer's column:
First, and most important, Johnson was and is his own man. You can't envy anyone coming in after the founder, Howard Schultz, retired. Schultz is a revered figure. Who knew how the minions would respond to the quiet, low key almost anonymous successor, especially one that's from tech, not from coffee?
Should Investors Pay Attention to Pfizer and Mylan?
Pfizer and Real Money Stock of the Day Mylan announced Monday morning that Pfizer's spinning off its off-patent drug business to combine with Mylan and create a new company.
But Cramer says that, while he's got an eye on Pfizer, he's more focused on another pharma company.
Hint: It's got a focus on cancer drugs.